Pyoderma gangrenosum
Pyoderma gangrenosum on harvinainen tulehduksellinen ihosairaus, jossa kivuliaista märkärakkuloista tai kyhmyistä tulee haavaumia, jotka kasvavat asteittain. Pyoderma gangrenosum ei ole tarttuva. Hoidot voivat sisältää kortikosteroideja, siklosporiinia tai erilaisia monoklonaalisia vasta-aineita. Vaikka se voi vaikuttaa kaiken ikäisiin ihmisiin, se vaikuttaa enimmäkseen 40- ja 50-vuotiaisiin.
☆ Saksan vuoden 2022 Stiftung Warentest -tuloksissa kuluttajien tyytyväisyys ModelDermiin oli vain hieman alhaisempi kuin maksullisiin telelääketieteen konsultaatioihin.
Haavaisesta paksusuolitulehduksesta kärsivän henkilön jalassa.
References
Pyoderma gangrenosum on harvinainen ihosairaus, joka aiheuttaa tuskallisia haavaumia, joiden reunat ovat punaiset tai purppuraiset. Se on luokiteltu tulehdukselliseksi sairaudeksi ja kuuluu ryhmään, jota kutsutaan neutrofiilisiksi dermatooseiksi. Pyoderma gangrenosum :n syy on monimutkainen, ja se sisältää sekä synnynnäiseen että adaptiiviseen immuniteettiin liittyviä ongelmia ihmisillä, jotka ovat geneettisesti alttiita. Viime aikoina tutkijat ovat keskittyneet karvatuppiin taudin mahdollisena lähtökohtana.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum is a rare inflammatory skin disease classified within the group of neutrophilic dermatoses and clinically characterized by painful, rapidly evolving cutaneous ulcers with undermined, irregular, erythematous-violaceous edges. Pyoderma gangrenosum pathogenesis is complex and involves a profound dysregulation of components of both innate and adaptive immunity in genetically predisposed individuals, with the follicular unit increasingly recognized as the putative initial target.
Pyoderma gangrenosum on harvinainen ihosairaus, joka aiheuttaa erittäin kivuliaita haavaumia. Vaikka emme täysin ymmärrä sen syytä, tiedämme, että siihen liittyy tiettyjen immuunisolujen lisääntynyt aktiivisuus. Taudin hoitaminen ei ole vielä helppoa. Meillä on erilaisia lääkkeitä, jotka heikentävät immuunijärjestelmää tai muokkaavat sen toimintaa. Näiden ohella keskitymme myös haavojen hoitoon ja kivun hallintaan. Kortikosteroidit ja syklosporiini ovat usein ensimmäinen hoitovaihtoehto, mutta viime aikoina on tutkittu enemmän biologisten hoitojen, kuten TNF-α-estäjien, käyttöä. Nämä biologiset aineet ovat yhä suositumpia, erityisesti potilailla, joilla on muita tulehdussairauksia, ja niitä käytetään aikaisemmin sairausprosessissa.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
Pyoderma gangrenosum is a rare neutrophilic dermatosis that leads to exceedingly painful ulcerations of the skin. Although the exact pathogenesis is not yet fully understood, various auto-inflammatory phenomena with increased neutrophil granulocyte activity have been demonstrated. Despite the limited understanding of the pathogenesis, it is no longer a diagnosis of exclusion, as it can now be made on the basis of validated scoring systems. However, therapy remains a major multidisciplinary challenge. Various immunosuppressive and immunomodulatory therapies are available for the treatment of affected patients. In addition, concomitant topical pharmacologic therapy, wound management and pain control should always be addressed. Corticosteroids and/or cyclosporine remain the systemic therapeutics of choice for most patients. However, in recent years, there has been an increasing number of studies on the positive effects of biologic therapies such as inhibitors of tumour necrosis factor-α; interleukin-1, interleukin-17, interleukin-23 or complement factor C5a. Biologics have now become the drug of choice in certain scenarios, particularly in patients with underlying inflammatory comorbidities, and are increasingly used at an early stage in the disease rather than in therapy refractory patients.
